Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Other Non-Current Assets (2020 - 2025)

Historic Other Non-Current Assets for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $2.1 million.

  • Tango Therapeutics' Other Non-Current Assets fell 1667.32% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 1667.32%. This contributed to the annual value of $2.6 million for FY2024, which is 2450.0% down from last year.
  • Tango Therapeutics' Other Non-Current Assets amounted to $2.1 million in Q3 2025, which was down 1667.32% from $2.1 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Other Non-Current Assets high stood at $4.0 million for Q1 2022, and its period low was $2.1 million during Q1 2025.
  • Over the past 5 years, Tango Therapeutics' median Other Non-Current Assets value was $2.6 million (recorded in 2023), while the average stood at $2.8 million.
  • Per our database at Business Quant, Tango Therapeutics' Other Non-Current Assets skyrocketed by 7391.3% in 2022 and then plummeted by 3582.5% in 2023.
  • Over the past 5 years, Tango Therapeutics' Other Non-Current Assets (Quarter) stood at $2.3 million in 2021, then surged by 73.91% to $4.0 million in 2022, then decreased by 15.0% to $3.4 million in 2023, then decreased by 24.5% to $2.6 million in 2024, then fell by 16.67% to $2.1 million in 2025.
  • Its Other Non-Current Assets stands at $2.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.1 million for Q1 2025.